Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress
10.06.2022 - – Treatment with PYRUKYND Associated with Early and Robust Hemoglobin Responses in Phase 3 ACTIVATE and Extension Studies; Approximately One-Third of Patients Achieved Normal Hemoglobin Levels at Least Once – – PYRUKYND-Treated Patients Reported ... Seite 1
Source: wallstreet-online.de